CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8
about
Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal BlockageUpdate on CD40 and CD154 blockade in transplant modelsNonhuman primate models of type 1 diabetes mellitus for islet transplantation.Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigsIn vitro testing of an anti-CD40 monoclonal antibody, clone 2C10, in primates and pigs.Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.Primate models in organ transplantationCostimulation Blockade in Kidney Transplantation: An UpdateBioengineering the Endocrine Pancreas: Intraomental Islet Transplantation Within a Biologic Resorbable Scaffold.Belatacept: a new era of immunosuppression?T-cell co-stimulatory blockade in transplantation: two steps forward one step back!Targeting co-stimulatory pathways: transplantation and autoimmunity.Potential and limitations of regulatory T-cell therapy in solid organ transplantation.Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected?T Cell Cosignaling Molecules in Transplantation.Crosstalk Between T and B Cells in the Germinal Center After Transplantation.Role of Memory T Cells in Allograft Rejection and ToleranceBelatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation.The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation.ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates.Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus: An in vivo study.Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig.The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions
P2860
Q26778646-67D430AD-09AA-4A26-9276-B2F912EF4E4FQ26798362-B7F0F88C-6B31-4D8F-8417-748E972813D3Q34441658-DE5D8C3D-7B04-4D73-A6DC-86CA706BD659Q35202459-78409497-6C98-4C30-AC6E-47F9B3DB478BQ36289120-82AACE16-EB46-402C-AB4A-EA5F268292D9Q36769110-8E90F83D-705B-4714-856E-FCBA611D42E4Q37122367-2341BFC7-D734-4BA0-A1FA-1DD89BB8990BQ37375148-EA002FD2-4CF7-4F9F-941B-DCE55658FBDEQ37741918-1367521F-6F7F-4554-9614-0B817B2F618DQ38044759-A3C795C9-FE1E-417A-B7A3-3BB936AF4FB8Q38148197-A34582AF-726A-4347-A6BC-A5344F56F7E9Q38150101-F36F5FB8-BE95-4A3A-BA0A-8AFB6624A06CQ38235166-4E60170C-824D-4D1F-B86D-FD82FFFA3FB6Q38445344-24DC0544-458F-4045-9A71-B81030C21D79Q38623790-AACC2C10-C4A4-468C-B373-57D0E84B867BQ38837473-CAF7A1DB-2F59-44B6-89C2-1B2C5D8A8B48Q39025865-2F12D9B6-0FA3-47CB-8047-81A19DBDA424Q39178547-1C4412EC-3B52-43C0-8A31-60C47AE0D0B8Q42235846-3EE363A2-0E03-473A-8F24-48B81E1E057EQ44770974-6F766D9C-71A5-4279-98E3-697558CC1695Q48032381-F6CA971D-B815-4247-8FEC-9CC5615A09B7Q49875978-D4E7EC2B-5295-4402-88B0-5C3125DE458EQ53145957-C0752DE3-A250-4D02-A366-50BDA413CD50Q57821796-0EFF6842-D5CE-4A48-8876-C08C1B46C322
P2860
CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
CTLA4Ig prevents alloantibody ...... the CD40-specific antibody 3A8
@ast
CTLA4Ig prevents alloantibody ...... the CD40-specific antibody 3A8
@en
type
label
CTLA4Ig prevents alloantibody ...... the CD40-specific antibody 3A8
@ast
CTLA4Ig prevents alloantibody ...... the CD40-specific antibody 3A8
@en
prefLabel
CTLA4Ig prevents alloantibody ...... the CD40-specific antibody 3A8
@ast
CTLA4Ig prevents alloantibody ...... the CD40-specific antibody 3A8
@en
P2093
P2860
P1476
CTLA4Ig prevents alloantibody ...... the CD40-specific antibody 3A8
@en
P2093
A P Turner
E A Strobert
F V Leopardi
I R Badell
M C Russell
P2860
P304
P356
10.1111/J.1600-6143.2012.04029.X
P407
P577
2012-03-28T00:00:00Z